CA2339992C - Orally disintegrable tablet forming a viscous slurry - Google Patents

Orally disintegrable tablet forming a viscous slurry Download PDF

Info

Publication number
CA2339992C
CA2339992C CA002339992A CA2339992A CA2339992C CA 2339992 C CA2339992 C CA 2339992C CA 002339992 A CA002339992 A CA 002339992A CA 2339992 A CA2339992 A CA 2339992A CA 2339992 C CA2339992 C CA 2339992C
Authority
CA
Canada
Prior art keywords
dosage form
weight
amount
mouth
weight based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002339992A
Other languages
English (en)
French (fr)
Other versions
CA2339992A1 (en
Inventor
John M. Siebert
Rajendra K. Khankari
Unchalee Kositprapa
S. Indiran Pather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of CA2339992A1 publication Critical patent/CA2339992A1/en
Application granted granted Critical
Publication of CA2339992C publication Critical patent/CA2339992C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002339992A 1998-08-12 1999-08-12 Orally disintegrable tablet forming a viscous slurry Expired - Fee Related CA2339992C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9626598P 1998-08-12 1998-08-12
US60/096,265 1998-08-12
US09/372,738 1999-08-11
US09/372,738 US6368625B1 (en) 1998-08-12 1999-08-11 Orally disintegrable tablet forming a viscous slurry
PCT/US1999/018400 WO2000009090A1 (en) 1998-08-12 1999-08-12 Orally disintegrable tablet forming a viscous slurry

Publications (2)

Publication Number Publication Date
CA2339992A1 CA2339992A1 (en) 2000-02-24
CA2339992C true CA2339992C (en) 2006-01-03

Family

ID=26791503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002339992A Expired - Fee Related CA2339992C (en) 1998-08-12 1999-08-12 Orally disintegrable tablet forming a viscous slurry

Country Status (9)

Country Link
US (1) US6368625B1 (enExample)
EP (1) EP1104288B1 (enExample)
JP (1) JP2002522471A (enExample)
AT (1) ATE326951T1 (enExample)
AU (1) AU742049B2 (enExample)
CA (1) CA2339992C (enExample)
DE (1) DE69931498T2 (enExample)
ES (1) ES2265188T3 (enExample)
WO (1) WO2000009090A1 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DE69836207T2 (de) 1997-03-28 2007-08-30 Eisai Co., Ltd. Orale pharmazeutische zusammensetzungen mit reduzierter bitterkeit durch geschmacksmaskiermittel
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE437632T1 (de) * 2000-03-01 2009-08-15 Eisai R&D Man Co Ltd Schnellzerfallende polyvinylhaltige tablette
JP4698000B2 (ja) * 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
GB0203984D0 (en) * 2002-02-20 2002-04-03 Mach Ind Etablissements Comsumable container
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
DE10244504A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
EP1603540A2 (en) * 2003-03-14 2005-12-14 Nirmal Mulye A process for preparing sustained release tablets
DE10311585A1 (de) * 2003-03-14 2004-09-23 Basf Ag Wirkstoffhaltige Adsorbate
WO2004098571A1 (en) * 2003-04-30 2004-11-18 Zicam, Llc Cold remedy composition comprising zinc salts
NZ544007A (en) 2003-05-07 2009-05-31 Samyang Corp Highly plastic granules for making fast melting tablets
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
MXPA06000702A (es) * 2003-07-23 2006-04-11 Perrigo L Co Composicion que contiene fibra celulosica.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
EP1695699A4 (en) * 2003-12-09 2012-08-22 Dainippon Sumitomo Pharma Co MEDICINAL GRAINS AND THE GRAINS CONTAINING SOLID PREPARATIONS
US20070036853A1 (en) * 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
EA010826B1 (ru) * 2003-12-31 2008-12-30 Сайма Лэбс Инк. Лекарственная форма фентанила для перорального применения, способ ее получения и способы лечения
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
EP1708685B1 (en) * 2003-12-31 2011-03-09 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering oxycodone
WO2005074658A2 (en) * 2004-01-30 2005-08-18 Glenmark Pharmaceuticals Inc., Usa Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
US20050170014A1 (en) * 2004-01-30 2005-08-04 Anandi Krishnan Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
KR20130116378A (ko) * 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US20060003003A1 (en) * 2004-06-28 2006-01-05 Bakker Johan A Oral sustained release formulation of tedisamil with gastric retention properties
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE602006007538D1 (de) * 2005-01-06 2009-08-13 Cima Labs Inc Geschmacksunterdrückungssystem für nicht geweichte arzneimittel
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20060281783A1 (en) * 2005-05-25 2006-12-14 Transoral Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2011109340A1 (en) 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
WO2014007972A2 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
WO2007056159A2 (en) * 2005-11-03 2007-05-18 Redpoint Bio Corporation Hydrazone derivatives and uses thereof
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2007143675A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008024364A2 (en) * 2006-08-22 2008-02-28 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008033545A2 (en) * 2006-09-15 2008-03-20 Redpoint Bio Corporation Triphenylphosphine oxide derivatives and uses thereof
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
AU2008214338A1 (en) * 2007-02-02 2008-08-14 Redpoint Bio Corporation Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release
US20100010031A1 (en) * 2007-02-09 2010-01-14 Yum Ii Su Transoral dosage forms comprising sufentanil and naloxone
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
EA201070715A1 (ru) 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
WO2010077878A1 (en) * 2008-12-15 2010-07-08 Fleming And Company, Pharmaceuticals Rapidly dissolving vitamin formulation and methods of using the same
US20100163805A1 (en) * 2008-12-31 2010-07-01 Youngtack Shim Agent-containing media and methods therefor
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011028671A1 (en) 2009-09-04 2011-03-10 Redpoint Bio Corporation Sweetness enhancers including rebaudioside a or d
EP2480097A1 (en) 2009-09-22 2012-08-01 Redpoint Bio Corporation Novel polymorphs of rebaudioside c and methods for making and using the same
WO2011067667A2 (en) 2009-12-02 2011-06-09 Eurand Pharmaceuticals Limited Fexofenadine microcapsules and compositions containing them
UY33173A (enExample) * 2010-01-08 2011-07-29 Eurand Inc
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
MX392155B (es) 2011-08-08 2025-03-21 Int Flavors & Fragrances Inc Composiciones y metodos para la biosintesis de vainillina o de beta-d-glucosido de vainillina.
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
ES2882530T3 (es) 2013-03-22 2021-12-02 Univ Nova Southeastern Partículas finas de epinefrina y métodos para uso de las mismas para el tratamiento de condiciones que responden a la epinefrina
EP3068227A4 (en) * 2013-11-11 2017-06-21 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
EP2880992A3 (en) 2013-12-05 2015-06-17 International Flavors & Fragrances Inc. Rebaudioside C and its stereoisomers as natural product sweetness enhancers
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
WO2019240740A1 (en) 2017-12-22 2019-12-19 Arasteh Ari Azhir Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
WO2020081952A1 (en) 2018-10-19 2020-04-23 Nova Southeastern University Sublingual epinephrine compositions including ph-modifying excipients and penetration enhancers and methods for use thereof
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011950A (en) 1959-05-19 1961-12-05 Colgate Palmolive Co Liquid composition containing discrete gaseous bodies
US3142621A (en) 1961-11-02 1964-07-28 Ciba Geigy Corp Alginate suspensions of oral pharmaceutical compositions with improved taste qualities
US3456049A (en) 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4414198A (en) 1982-04-23 1983-11-08 Joseph Michaelson Rapidly disintegrable tablet composition and method
US4454110A (en) 1982-05-24 1984-06-12 Forsyth Dental Infirmary For Children Self-gelling liquid composition for topical application in the oral cavity
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8426152D0 (en) 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4687662A (en) * 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5624683A (en) 1986-08-06 1997-04-29 Eisai Co., Ltd. Sustained-release multi-granule tablet
US5288500A (en) 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
US5215752A (en) 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5273823A (en) 1988-10-11 1993-12-28 The Dow Chemical Company Shaped articles containing copolymers of polybenzazoles
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5102664A (en) 1989-07-19 1992-04-07 Day Charles E Good-tasting gritty drug formulations
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69231856T2 (de) 1991-08-30 2002-03-28 Showa Yakuhin Kako Co., Ltd. Trockene gelzusammensetzung
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5545423A (en) 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5368862A (en) 1991-12-18 1994-11-29 Merck & Co., Inc. Sustained release tablets containing alginate
CA2130487A1 (en) * 1992-02-18 1993-08-19 Kouichi Nakamichi Fast soluble tablet
US5422122A (en) 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
IL104283A (en) 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
FR2732217B1 (fr) * 1995-03-29 1997-06-06 Hesnard Xavier Forme d'administration solide a usage oral
JP2919771B2 (ja) * 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
WO1997047287A1 (en) * 1996-06-14 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
ATE291930T1 (de) * 1996-07-12 2005-04-15 Daiichi Seiyaku Co Schnell zerfallende, druckgeformte materialien sowie prozess zu deren herstellung
FR2753097A1 (fr) * 1996-09-11 1998-03-13 Barrau Francois Gel aqueux ou hydroalcoolique extemporane a viscosite controlee
EP1007012A4 (en) * 1996-10-01 2006-01-18 Cima Labs Inc TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
JPH10182436A (ja) * 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
JPH10167958A (ja) * 1996-12-09 1998-06-23 Sankyo Co Ltd ロキソプロフェンナトリウム類を含有する口腔内速溶性製剤及びその製造方法
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations

Also Published As

Publication number Publication date
EP1104288A1 (en) 2001-06-06
ATE326951T1 (de) 2006-06-15
CA2339992A1 (en) 2000-02-24
US6368625B1 (en) 2002-04-09
ES2265188T3 (es) 2007-02-01
DE69931498T2 (de) 2007-03-01
AU5482399A (en) 2000-03-06
JP2002522471A (ja) 2002-07-23
AU742049B2 (en) 2001-12-13
EP1104288A4 (en) 2003-04-16
DE69931498D1 (de) 2006-06-29
WO2000009090A1 (en) 2000-02-24
EP1104288B1 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
CA2339992C (en) Orally disintegrable tablet forming a viscous slurry
JP2002522471A5 (enExample)
AU726336B2 (en) Rapidly dissolving robust dosage form
CA2335566C (en) Effervescent drug delivery system for oral administration
US5178878A (en) Effervescent dosage form with microparticles
EP1274398B1 (en) Methods for thepreparation of effervescent granules
US6365182B1 (en) Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
ES2462536T3 (es) Comprimido orodispersable multicapa
EP1478346A1 (en) Fast disintegrating tablets
US6080427A (en) Cefadroxil monohydrate tablet formulation
EP1688131A1 (en) Orally disintegratable tablet forming a viscous slurry
HK1137654B (en) Rapidly dissolving robust dosage form
HK1147055A (en) Rapidly dissolving robust dosage form
AU2005202472A1 (en) Effervescent drug delivery system for oral administration

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed